DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Employees - 21, CEO - Dr. James E. Brown D.V.M., Sector - Healthcare, Country - US, Market Cap - 18.94M

Altman ZScore(max is 10): -60.79, Piotroski Score(max is 10): 1, Working Capital: $1739000, Total Assets: $14360000, Retained Earnings: $-601562000, EBIT: -15935000, Total Liabilities: $8566000, Revenue: $525000

AryaFin Target Price - $0.09 - Current Price $0.61 - Analyst Target Price $5.00